Farnesyl Transferase Expression Determines Clinical Response to the Docetaxel-Lonafarnib Combination in Patients with Advanced Malignancies

BACKGROUND: Lonafarnib (LNF) is a protein farnesyl transferase (FTase) inhibitor that has shown synergistic activity with taxanes in preclinical models and early stage clinical trials. Preclinical findings suggested tubulin acetylation and FTase expression levels may be important determinants of dru...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Kauh, John, Chanel-Vos, Chantal, Escuin, Daniel, Fanucchi, Michael P, Harvey, R. Donald, Saba, Nabil, Shin, Dong M., Gal, Anthony, Pan, Lin, Kutner, Michael, Ramalingam, Suresh S., Bender, Laura, Marcus, Adam, Giannakakou, Paraskevi, Khuri, Fadlo R.
Formato: Artigo
Idioma:Inglês
Publicado em: 2011
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3131496/
https://ncbi.nlm.nih.gov/pubmed/21365629
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados